Skip to content

Clinical trials

Carcinoma, Non-Small-Cell Lung trials with no applicable phase and unknown status

Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.

Filters: Condition: Carcinoma, Non-Small-Cell Lung Phase: Not applicable Status: Unknown status Clear all

116 trials match Source: ClinicalTrials.gov registrations

Trials started per year

By phase, 2000 to 2026.

Trials started per year
CategoryTrials
20041
20061
20071
20081
20094
20106
20114
20121
20134
20143
20155
20166
20176
201813
201914
20205
202116
202211
20237
20244

Status

Trials by registry status. Select a bar to filter.

Trials by status
CategoryTrials
Unknown status116

Top lead sponsors

A sponsor with a page on Pharma Observatory links to it.

Top lead sponsors
CategoryTrials
National Taiwan University Hospital4
Guizhou Medical University3
Shanghai 10th People's Hospital3
Tianjin Medical University Cancer Institute and Hospital3
Beijing Chest Hospital2
Istituto Clinico Humanitas2
Second Affiliated Hospital, Zhejiang University, School of Medicine2
Shandong Cancer Hospital and Institute2
Sun Yat-sen University2
The Netherlands Cancer Institute2

Top conditions

MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.

Top conditions
CategoryTrials
Carcinoma, Non-Small-Cell Lung116
Lung Neoplasms21
Small Cell Lung Carcinoma9
Breast Neoplasms4
Colorectal Neoplasms3
Melanoma3
Carcinoma2
Colonic Neoplasms2
Esophageal Neoplasms2
Head and Neck Neoplasms2

Trials

Showing 1 to 25 of 116. Each trial links to its page on Pharma Observatory.

16 more trials match. See them on Pharma Observatory

Recently changed trials

Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.

No changes to these trials in the last 7 days.

Go deeper on Pharma Observatory

Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.